Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
Go back to Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting(NYSE: RCUS) | Delayed: 18.91 +0.70 (3.84%) | |||||
---|---|---|---|---|---|---|
Previous Close | $18.21 | 52 Week High | $ | |||
Open | $18.30 | 52 Week Low | $ | |||
Day High | $18.98 | P/E | N/A | |||
Day Low | $18.18 | EPS | $ | |||
Volume | 170,914 |